Tuesday, January 23, 2018

Combating Frailty's Fatal Impact in Liver Disease

Advice for Combating Frailty's Fatal Impact in Liver Disease
Rowen K. Zetterman, MD
January 22, 2018

Dr Rowen Zetterman on the various ways in which frailty imperils outcomes in liver disease, and the most useful strategies for addressing them.

Diagnosing Frailty in Patients With Cirrhosis 
Frailty also increases the risk for morbidity and mortality in patients with chronic liver disease.[6,7] Sarcopenia (loss of muscle mass) and frailty may not directly correlate with the clinical severity of liver disease, and must be carefully sought to establish the diagnosis.[6]

Using observation alone to diagnose frailty in patients with end-stage liver disease is inadequate, because frailty may not be recognized by clinicians until late in the course of disease or simply be overlooked in well-groomed patients, some women, and those with obesity. Using body mass index as an indicator of malnutrition and frailty can be deceptive, because it fails to consider the functional issues of frailty. Multiple clinical measures of frailty have been published using a combination of findings, such as unintentional weight loss, reduced walking or gait speed, muscle weakness, and evidence of reduced physical activity.[1,2,7,8]

Free registration may be required

Co-managing HIV, Hepatitis C, and Opioid Abuse

Co-managing HIV, Hepatitis C, and Opioid Abuse
Naveed Saleh, MD, MS
January 23, 2018

Infection and Opioids
Effective antiretroviral treatments for HIV and hepatitis C exist and are widely available. In fact, treatment for hepatitis C is curative, which hardly seemed imaginable only a few short years ago. But despite there being effective treatments for these diseases, barriers exist that make their treatment difficult. Chief among these barriers is intravenous use of opioids.

The stark reality is that people with hepatitis C or HIV, or both diseases, are much more likely to die of drug overdose than of chronic illness itself. Furthermore, according to the Centers for Disease Control and Prevention, in 2014 death from drug overdose was more common than death caused by motor vehicle accidents or firearms. Of note, 80% of people who inject drugs and are HIV-positive also have hepatitis C.

At IDWeek 2017, managing infectious disease in opioid users was an important topic of coverage. In a lecture titled "Co-management of Opioid Treatment, HIV, and Hepatitis C Treatment," Brianna Norton, DO, MPH, an assistant professor of infectious disease and internal medicine at the Albert Einstein College of Medicine, discussed evidence-based approaches to treating opioid use disorder in patients with HIV and hepatitis C.

Diagnosis & management of hepatitis C infection in primary care settings

Diagnosis & management of hepatitis C infection in primary care settings
Debra Guss, MS, APRN, ANP-C1, Jagannath Sherigar, MD1, Paul Rosen, D2,andSmrutiR.Mohanty, MD, MS FACP

Hepatitis C virus (HCV) infection is a significant health problem worldwide, and is the leading cause of cirrhosis, hepatocellular carcinoma, and liver transplantation in the United States. The management of HCV has changed significantly over the last 5 years, as treatments have become simpler and more efficacious. Medication efficacy is now greater than 90%, with a high barrier to resistance and few side effects. This review is a collaboration between primary care and hepatology providers to explore all aspects of HCV management: acute versus chronic HCV infection, transmission and testing, and diagnosis and treatment. Specific medications for the treatment of HCV infection are considered, and patient and medication factors including genotype, liver disease status, and comorbidities affecting medication choice are discussed. This is a new era for the management of HCV infection, and interested primary care physicians, family doctors, and general internists can be at the forefront of diagnosis, management, and treatment of HCV.

Full Text
Shared by Henry E. Chang on Twitter

Misperceptions' keep some from agreeing to donate organs after death

Misperceptions' keep some from agreeing to donate organs after death
Last Updated: 2018-01-22
By Carolyn Crist

(Reuters Health) - Although most Americans say they're willing to be an organ donor after they die, some people never sign up because they're unsure about what could happen to them in a medical emergency, according to a new study.

In particular, survey respondents reported concerns about receiving adequate medical care if they registered to donate organs after they died.

The medical community "(needs) to address these misperceptions," said lead study author Dr. Marty Sellers, a transplant surgeon at Emory University in Atlanta, Georgia, in a phone interview.

In 2017, more than 10,000 deceased donors contributed to nearly 29,000 transplants in the U.S., according to the U.S. Organ Procurement and Transplantation Network. Living donors contributed organs for an additional 6,000 transplants.

Cold or flu? Here's how to tell, plus your flu vaccine questions answered

Cold or flu? Here's how to tell, plus your flu vaccine questions answered
Posted 9:03 AM
By Julie Washington, The Plain Dealer

CLEVELAND, Ohio -- You're coughing, sniffling and sneezing and feeling lousy, but is it a cold, or the flu?

It's important to know the difference, because the flu is much more serious than a cold, and lasts longer, explained Dr. Amy Edwards, associate medical director of Pediatric Infection Control at University Hospitals Rainbow Babies and Children's Hospital.

Three flu-related deaths were reported in Cuyahoga County during the week of Jan. 7-13, bringing to five the total number of flu-related deaths this season. The Centers for Disease Control and Prevention last week reported widespread flu activity across the country, with 10 pediatric flu-related deaths during this flu season so far.

Getting a flu shot is the best way to protect yourself and others from getting a serious case of the flu.

Here is Edwards' explanation of the difference between a cold and the flu.

Q: What is a cold?

A: A cold is a catch-all term for an upper respiratory infection caused by many different viruses, Edwards said. A cold's runny nose, cough, fever and sore throat lasts up to five or six days.

The Effect of Shorter Treatment Regimens for Hepatitis C on Population Health and Under Fixed Budgets.

In case you missed it

The Effect of Shorter Treatment Regimens for Hepatitis C on Population Health and Under Fixed Budgets.
Morgan JR, et al. Open Forum Infect Dis. 2018.

Full Text
View Online

Background: Direct acting antiviral hepatitis C virus (HCV) therapies are highly effective but costly. Wider adoption of an 8-week ledipasvir/sofosbuvir treatment regimen could result in significant savings, but may be less efficacious compared with a 12-week regimen. We evaluated outcomes under a constrained budget and cost-effectiveness of 8 vs 12 weeks of therapy in treatment-naïve, noncirrhotic, genotype 1 HCV-infected black and nonblack individuals and considered scenarios of IL28B and NS5A resistance testing to determine treatment duration in sensitivity analyses.

Methods: We developed a decision tree to use in conjunction with Monte Carlo simulation to investigate the cost-effectiveness of recommended treatment durations and the population health effect of these strategies given a constrained budget. Outcomes included the total number of individuals treated and attaining sustained virologic response (SVR) given a constrained budget and incremental cost-effectiveness ratios.

Results: We found that treating eligible (treatment-naïve, noncirrhotic, HCV-RNA <6 million copies) individuals with 8 weeks rather than 12 weeks of therapy was cost-effective and allowed for 50% more individuals to attain SVR given a constrained budget among both black and nonblack individuals, and our results suggested that NS5A resistance testing is cost-effective.

Conclusions: Eight-week therapy provides good value, and wider adoption of shorter treatment could allow more individuals to attain SVR on the population level given a constrained budget. This analysis provides an evidence base to justify movement of the 8-week regimen to the preferred regimen list for appropriate patients in the HCV treatment guidelines and suggests expanding that recommendation to black patients in settings where cost and relapse trade-offs are considered.

Hepatocellular Carcinoma Screening in Patients Treated for Hepatitis C

The American Journal of Medicine
February 2018 Volume 131, Issue 2, Page e79

Letter to the editor
Hepatocellular Carcinoma Screening in Patients Treated for Hepatitis C
Harsh N. Patel, MD, Jason R. Stibbe, MD, Meghana Vellanki, MD, Harold Paul, MD

Article reference -  Hepatocellular Carcinoma Screening Associated with Early Tumor Detection and Improved Survival Among Patients with Cirrhosis in the US

Fla DOI: http://dx.doi.org/10.1016/j.amjmed.2017.09.036

To the Editor:
We have read your article by Singal et al1 with great interest, which discussed hepatocellular carcinoma screening being associated with early tumor detection and improved survival among patients with cirrhosis in the United States. The study clearly highlighted the importance of performing hepatocellular carcinoma screening in patients with cirrhosis; however, what is of concern is that more than half of the cases of hepatocellular carcinoma were found secondary to symptoms or incidentally, rather than through the hepatocellular carcinoma screening algorithm. Although adherence to screening was improved with subspecialty referral, patients are largely cared for by primary care physicians—highlighting a critical area in need of intervention.

In this study, the most common cause for cirrhosis in the population studied was hepatitis C virus at 57.2%; since 2013 there has been a shift in the treatment of hepatitis C viral therapy with direct-acting antivirals. Historically, interferon-based regimens have been the mainstay of anti–hepatitis C virus therapy, yielding hepatitis C virus cure or sustained virologic response in approximately 50% of patients.2 Recently developed direct-acting antivirals, which directly target the viral protease, polymerase, or nonstructural proteins, have revolutionized interferon-free regimens leading to an improved rate of achieving sustained virologic response, approaching or surpassing 90%.3

Although rates of hepatitis C virus–associated hepatocellular carcinoma will decrease significantly after the widespread adoption of direct-acting antivirals, there remains a persistent risk for hepatocellular carcinoma among patients with advanced fibrosis who have achieved sustained virologic response.4 The most well-established risk factor for developing hepatocellular carcinoma after a sustained virologic response in patients with hepatitis C virus is advanced fibrosis or cirrhosis.5 In a retrospective cohort study of 562 patients with sustained virologic response, the 5-year survival rate for those who received regular hepatocellular carcinoma screening (ultrasonography at least every 6 months) was 93%, whereas it was 60% for those who did not.4 As such, suggestion would be that individuals with hepatitis C virus with advanced fibrosis treated with anti–hepatitis C virus therapy and who have a sustained virologic response should continue to be screened regularly for hepatocellular carcinoma because the risk of disease progression, including hepatocellular carcinoma development, is not completely eliminated after sustained virologic response. Guidance should be provided to primary care providers to ensure the increasing population of patients with sustained virologic response after treatment for hepatitis C virus are maintained in the patient population needing screening.

The Reply
Gregory Seymann, MD, SFHM Correspondence information about the author MD, SFHM Gregory Seymann Email the author MD, SFHM Gregory Seymann , Robert El-Kareh, MD, MS, MPH, Gabrielle Schaefer, MD, Jennifer Quartarolo, MD

DOI: http://dx.doi.org/10.1016/j.amjmed.2017.09.037

The authors have reviewed the thoughtful commentary by Ayubi and Safiri on our article and appreciate the interest in our work.1

Ayubi and Safiri contend that our attempt to validate the Yale New Haven Readmission Risk Score in a different population of patients with pneumonia is limited by a lack of methodological transportability, given we incorporated new variables of functional status and social support that were not tested in the original study. We refer the reader to Table 2, in which we report modeling of the variables in the original Yale New Haven Readmission Risk Score, as well as modeling with the new variables. They also raise the concern for need of cross-validation in our methodology. Had we found significant contribution by our new predictors, then we would have pursued cross-validation to ensure that those results were not due to overfitting our sample. However, because our overall results were consistent with the larger study that developed the Yale New Haven Readmission Risk Score and our new predictors were not found to have a significant contribution, we did not pursue cross-validation.

They note concerns about selection bias and characterize our sample as a convenience sample. As is detailed in the “Methods” section, we included all patients hospitalized with pneumonia at our institution over a 1-year period. We respectfully disagree that a selection bias would be introduced by using a complete sample, although the limitations of a single-center sample, addressed in our discussion, still apply.

We agree with the authors that the addition of functional status and social support to the model did not produce clinically significant improvement in the predictive power of the model. This is pointed out in the “Discussion” and “Conclusions,” although we acknowledged that more robust markers of these variables may yield a more meaningful comparison.

Regarding the authors' question about our model-building methodology, we chose the predictors of the model a priori and developed our logistic regression model on the basis of those selections. We did not use other techniques to add or remove any predictors.

Risks for Hepatitis B Reactivation with Newer Hep C Treatments Detailed

Medical News |

January 22, 2018
Risks for Hepatitis B Reactivation with Newer Hep C Treatments Detailed
By Amy Orciari Herman

Edited by Susan Sadoughi, MD, and André Sofair, MD, MPH

About a quarter of patients with chronic hepatitis B infection experience reactivation of the virus when they receive direct-acting antivirals (DAAs) for hepatitis C infection, according to a meta-analysis in the Lancet Gastroenterology and Hepatology.

The analysis included 17 observational studies among over 1600 patients with chronic or resolved HBV infection who were treated with interferon-free DAA regimens (e.g., ledipasvir plus sofosbuvir) for chronic HCV. Some 24% of those with chronic HBV infection — versus 1.4% of those with resolved infection — had HBV reactivation during treatment. Additionally, 9% of those with chronic HBV experienced hepatitis related to HBV reactivation, versus none of those with resolved HBV.

The authors say their findings "support the use of antiviral prophylaxis in patients with chronic HBV and HCV coinfection" being treated with DAAs. They add, "By contrast, patients with resolved HBV infection might only require close [alanine aminotransferase] or HBV DNA monitoring, or both."

LINK(S): Lancet Gastroenterology and Hepatology article (Free abstract)

Background: Recent NEJM Journal Watch Infectious Diseases coverage of HBV reactivation during HCV treatment (Free)

HCV Next - ‘Think Outside the Box’ to Finance HCV Elimination

The following articles appeared in the January/February print edition of HCV NEXT, provided online at Healio.

Begin here....

Friday, January 19, 2018

Exposure to previous cART is associated with significant liver fibrosis and cirrhosis in human immunodeficiency virus-infected patients

Exposure to previous cART is associated with significant liver fibrosis and cirrhosis in human immunodeficiency virus-infected patients
Evrim Anadol , Kristina Lust , Christoph Boesecke, Carolynne Schwarze-Zander, Raphael Mohr, Jan-Christian Wasmuth, Jürgen Kurt Rockstroh , Jonel Trebicka

Published: January 18, 2018

Full Text
Download PDF
View Online

Combined antiretroviral therapy (cART) has improved survival in HIV-patients. While the first antiretrovirals, which became available in particular D-drugs (especially didanosine and stavudine) and unboosted protease inhibitors, may impair liver function, the modern cART seems to decrease liver fibrosis. This study assessed the influence of exposure to previous antiretrovirals on liver fibrosis in HIV-infected patients.

This observational cross-sectional single-center study recruited 333 HIV patients and assessed liver fibrosis using transient elastography (TE).

83% were male with a median age of 45, while 131 were co-infected with viral hepatitis. Overall, 18% had significant fibrosis and 7.5% had cirrhosis. 11% of HIV mono-infected patients had significant fibrosis and 2% had cirrhosis. HCV infection (OR:5.3), history of exposure to didanosine (OR:2.7) and HIV load below 40copies/mL (OR:0.5) were independently associated with significant fibrosis, while HCV (OR:5.8), exposure to didanosine (OR:2.9) and azidothymidine (OR:2.8) were independently associated with cirrhosis. Interestingly, in HIV mono-infected patients, a HIV-load below 40copies/mL (OR:0.4) was independently associated with significant fibrosis, and didanosine (OR:20.8) with cirrhosis.

In conclusion, history of exposure to didanosine and azidothymidine continues to have an impact on the presence of liver cirrhosis in HIV patients. However, HCV co-infection and ongoing HIV-replication have the strongest effect on development of significant fibrosis in these patients.

Full Text: http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0191118

Flu may be spread just by breathing

It is easier to spread the influenza virus (flu) than previously thought, according to a new University of Maryland-led study released today. People commonly believe that they can catch the flu by exposure to droplets from an infected person's coughs or sneezes or by touching contaminated surfaces. But, new information about flu transmission reveals that we may pass the flu to others just by breathing.

The study "Infectious virus in exhaled breath of symptomatic seasonal influenza cases from a college community," published in the Proceedings of the National Academy of Sciences, provides new evidence for the potential importance of airborne transmission because of the large quantities of infectious virus researchers found in the exhaled breath from people suffering from flu.

"We found that flu cases contaminated the air around them with infectious virus just by breathing, without coughing or sneezing," explained Dr. Milton, M.D., MPH, professor of environmental health in the University of Maryland School of Public Health and lead researcher of this study. "People with flu generate infectious aerosols (tiny droplets that stay suspended in the air for a long time) even when they are not coughing, and especially during the first days of illness. So when someone is coming down with influenza, they should go home and not remain in the workplace and infect others."

Researchers from the University of Maryland, San Jose State University, Missouri Western State University and University of California, Berkeley contributed to this study funded by the Centers for Disease Control and Prevention (CDC) and the National Institutes of Health.

Dr. Milton and his research team captured and characterized influenza virus in exhaled breath from 142 confirmed cases of people with influenza during natural breathing, prompted speech, spontaneous coughing, and sneezing, and assessed the infectivity of naturally occurring influenza aerosols. The participants provided 218 nasopharyngeal swabs and 218 30-minute samples of exhaled breath, spontaneous coughing, and sneezing on the first, second, and third days after the onset of symptoms.

The analysis of the infectious virus recovered from these samples showed that a significant number of flu patients routinely shed infectious virus, not merely detectable RNA, into aerosol particles small enough to present a risk for airborne transmission.

Surprisingly, 11 (48%) of the 23 fine aerosol samples acquired in the absence of coughing had detectable viral RNA and 8 of these 11 contained infectious virus, suggesting that coughing was not necessary for infectious aerosol generation in the fine aerosol droplets. In addition, the few sneezes observed were not associated with greater viral RNA copy numbers in either coarse or fine aerosols, suggesting that sneezing does not make an important contribution to influenza virus shedding in aerosols.

"The study findings suggest that keeping surfaces clean, washing our hands all the time, and avoiding people who are coughing does not provide complete protection from getting the flu," said Sheryl Ehrman, Don Beall Dean of the Charles W. Davidson College of Engineering at San José State University. "Staying home and out of public spaces could make a difference in the spread of the influenza virus."

According to the authors, the findings could be used to improve mathematical models of the risk of airborne influenza transmission from people with symptomatic illness and to develop more effective public health interventions and to control and reduce the impact of influenza epidemics and pandemics. Improvements could be made to ventilation systems to reduce transmission risk in offices, school classrooms and subway cars, for example. Meanwhile, we can all heed the advice to stay home, if possible, when we are beginning to get sick to prevent even greater numbers of flu cases. And, get vaccinated -- it is not perfect but does prevent a significant amount of severe illness.


First-Time Data for Merck’s KEYTRUDA® (pembrolizumab) in Patients with Previously Treated Advanced Hepatocellular Carcinoma (HCC) to be Presented at 2018 ASCO GI Symposium

First-Time Data for Merck’s KEYTRUDA® (pembrolizumab) in Patients with Previously Treated Advanced Hepatocellular Carcinoma (HCC) to be Presented at 2018 ASCO GI Symposium

KENILWORTH, N.J.--(BUSINESS WIRE)--Jan. 19, 2018-- Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced findings from the registrational phase 2 KEYNOTE-224 trial investigating the use of KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, in patients with advanced hepatocellular carcinoma (HCC), the most common type of liver cancer, who were previously treated with systemic therapy (sorafenib). Results showed an overall response rate (ORR) of 16.3 percent (95% CI, 9.8-24.9) (n=17/104) with KEYTRUDA as monotherapy. Data also include six-month overall survival (OS) and progression-free survival (PFS) rates. The findings will be presented at the 2018 American Society of Clinical Oncology Gastrointestinal (ASCO GI) Cancers Symposium in San Francisco in an oral presentation on Friday, Jan. 19, from 1:10-1:15 p.m. PT (Location: Level 3 – Room 3014) (Abstract #209).

“There continues to be a significant need for new options in the treatment of advanced hepatocellular carcinoma,” said Andrew Zhu, M.D., Ph.D., lead investigator and director of liver cancer research at Massachusetts General Hospital Cancer Center. “The durable responses observed with KEYTRUDA monotherapy in this difficult-to-treat cancer are encouraging.”

“Merck is committed to understanding the clinical benefit of KEYTRUDA monotherapy across a range of gastrointestinal cancers, including advanced liver cancer,” said Dr. Roger Dansey, senior vice president and therapeutic area head, oncology late-stage development, Merck Research Laboratories. “The findings from this study demonstrate the potential of KEYTRUDA in patients with advanced HCC following prior systemic therapy and support the advancement of our clinical development program in this cancer type.”

Merck has the industry’s largest immuno-oncology clinical research program, which currently involves more than 650 trials studying KEYTRUDA (pembrolizumab) across a wide variety of cancers and treatment settings, including multiple gastrointestinal disorders such as HCC and gastroesophageal cancer.

The KEYTRUDA clinical program seeks to understand the role of KEYTRUDA across cancers and the factors that may predict a patient’s likelihood of benefitting from treatment with KEYTRUDA, including exploring several different biomarkers.

Data in Previously Treated Advanced HCC, KEYNOTE-224 (Abstract #209)

KEYNOTE-224 is a registrational, open-label phase 2 trial investigating KEYTRUDA monotherapy in patients with advanced HCC who had previously received systemic therapy with sorafenib. The primary endpoint is ORR; secondary endpoints include duration of response, disease control rate, time to progression, PFS and OS.

Findings presented at ASCO GI were based on data from 104 evaluable patients, previously treated with sorafenib, who received one or more doses of KEYTRUDA (200 mg intravenous infusion on day 1 of each 3-week cycle for up to 35 administrations). Data showed an ORR of 16.3 percent (95% CI, 9.8-24.9) (n=17/104) with a complete response rate of one percent (95% CI, 0.0-5.2) and a partial response rate of 15.4 percent (95% CI, 9.1-23.8). ORR was similar across subgroups with different etiology, including Hepatitis B and Hepatitis C positive patients. At the time of analysis, the median duration of response was 8.2 months (range: 2.3+ to 8.3+) with 94 percent of responses ongoing for six months or longer (calculated per Kaplan-Meier method). The disease control rate was 61.5 percent (95% CI, 51.5-70.9) (n=64/104). The median PFS was 4.8 months (95% CI, 3.4-6.6) with a six-month PFS rate of 43.1 percent. The median OS had not been reached at the time of analysis (95% CI, 9.4-not reached) with a six-month OS rate of 77.9 percent.

The safety profile of KEYTRUDA was consistent with that observed in previously reported studies. The treatment-related adverse events (any grade occurring in 10% or more of patients) were fatigue (12.5%), increased aspartate aminotransferase (9.6%), diarrhea (9.6%) and pruritus (21.2%). Grade 3-5 treatment-related adverse events occurred in 26 (25%) patients and there was one treatment-related death. Immune-mediated adverse events occurred in 2.9 percent of patients. Seven patients discontinued treatment due to treatment-related adverse events.

About Hepatocellular Carcinoma (HCC)
Hepatocellular carcinoma (HCC) is the most common type of liver cancer in adults. Worldwide, more than 782,000 new cases of liver cancer were diagnosed in 2012. In the U.S., the incidence of liver cancer has more than tripled since 1980 and it is estimated that 42,220 new cases will be diagnosed in this year. In Europe, around 63,500 new cases were diagnosed in 2012. Risk factors for liver cancer include gender, ethnicity, chronic viral hepatitis (Hep-B or Hep-C) infection, cirrhosis, heavy alcohol abuse and obesity. HCC – which is frequently diagnosed at an advanced stage – has one of the highest mortality rates of solid cancers, with a 5-year survival rate of less than 15 percent.

About KEYTRUDA ® (pembrolizumab) Injection 100mg
KEYTRUDA is an anti-PD-1 therapy that works by increasing the ability of the body’s immune system to help detect and fight tumor cells. KEYTRUDA is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby activating T lymphocytes which may affect both tumor cells and healthy cells.
KEYTRUDA (pembrolizumab) Indications and Dosing

Continue reading:

Thursday, January 18, 2018

Healthcare costs of liver cancer in Veterans with cirrhosis in the USA

Healthcare costs of liver cancer in Veterans with cirrhosis in the USA

January's issue of the Clinical Gastroenterology & Hepatology investigates healthcare costs related to treatment of hepatocellular carcinoma among Veterans with cirrhosis in the United States.

It is important to quantify medical costs associated with hepatocellular carcinoma (HCC), the incidence of which is rapidly increasing in the United States, for development of rational healthcare policies related to liver cancer surveillance and treatment of chronic liver disease.

Dr David Kaplan and colleagues aimed to comprehensively quantify healthcare costs for HCC among patients with cirrhosis in an integrated health system and develop a model for predicting costs that is based on clinically relevant variables.

The research team noted that 3 years subsequent to liver cancer diagnosis, costs accrued by patients included in the Veteran’s Outcome and Cost Associated with Liver disease cohort were compiled by using the Department of Veterans Affairs Corporate Data Warehouse.

3-year total cost of care in HCC patients was $154,688
Clinical Gastroenterology & Hepatology

The cohort includes all patients with HCC diagnosed in 2008–2010 within the VA with 100% chart confirmation as well as chart abstraction of tumor and clinical characteristics.

Cancer cases were matched 1:4 with non-cancer cirrhosis controls on the basis of severity of liver disease, age, and comorbidities to estimate background cirrhosis-related costs.

The team's analysis included 3188 cases of HCC and 12,722 controls.

The researchers found that the mean 3-year total cost of care in HCC patients was $154,688 compared with $69,010 in matched cirrhotic controls, yielding an incremental cost of $85,679, and 65% of this value reflected increased inpatient costs.

The research team observed that receipt of transplantation, Barcelona Clinic Liver Cancer (BCLC) stage, liver disease etiology, hospital academic affiliation, use of multidisciplinary tumor board, and identification through surveillance were associated with cancer-related costs.

Multivariable generalized linear models incorporating transplantation status, BCLC stage, and multidisciplinary tumor board presentation accurately predicted liver cancer–related costs.

Dr Kaplan's team concludes, "In a model developed to comprehensively quantify healthcare costs for HCC among patients with cirrhosis in an integrated health system, we associated receipt of liver transplantation, BCLC stage, and multidisciplinary tumor board with higher costs."

"Models that predict total costs on the basis of receipt of liver transplantation were constructed and can be used to model cost-effectiveness of therapies focused on HCC prevention."

Summary: http://www.gastrohep.com/news/news.asp?id=112988
Clin Gastroenterol Hepatol 2018: 16(1): 106–114.e5
18 January 2018

Editorial: direct-acting antivirals significantly improve quality of life in patients with HCV


Editorial: direct-acting antivirals significantly improve quality of life in patients with hepatitis C virus infection 
Authors S. Sanagapalli, M. Danta

First published: 17 January 2018
DOI: 10.1111/apt.14467

Linked Content
This article is linked to Younossi et al and Younossi papers. To view these articles visit https://doi.org/10.1111/apt.14423 and https://doi.org/10.1111/apt.14481.

The effect of direct-acting antiviral chronic Hepatitis C (HCV) therapies on patients’ quality of life has been a topic of minor attention compared with their impressive effects on virological endpoints. Yet, therapeutic benefits on quality of life are important to patients, and knowledge regarding such benefits may be an important tool in improving compliance in real-world scenarios.[1] For this reason, Younossi and colleagues are to be commended for their study, which describes clinically significant improvements in almost all measured physical and mental health-related quality of life outcomes following therapy with sofosbuvir and velpatasvir with or without voxilaprevir.[2] This replicates findings from other direct-acting antiviral regimens, but also confirms our own observations from clinical experience using these drugs.

Comparison with quality of life data from the interferon era may help us to tease out the mechanisms behind these findings. First, impairments in both mental and physical aspects of quality of life have long been described in chronic HCV, with or without cirrhosis, using the SF-36, one of the four instruments used in this study.[3] Second, very similar improvements in quality of life parameters were described 24 weeks after completion of interferon-based therapy, with the benefit confined only to those with sustained virological response.[4] More recent data comparing interferon-containing to interferon-free regimens clearly demonstrates that while both regimens result in equivalent improvements in quality of life (in responders) post therapy, the interferon-containing treatments are associated with significant worsening of quality of life during therapy. In contrast, quality of life seems to be improved early during interferon-free therapy and improves further following completion of successful treatment.[5, 6] Taken cumulatively we can infer that virological clearance plays a key role in improvement of quality of life, but cannot be the only factor, since improvement continues long after the virus has completely cleared from the serum.

What might such other factors be? The authors propose that improvement of liver function may play a role, though this still fails to explain the persistent improvement in benefit in non-cirrhotics post therapy. On the other hand, cerebral inflammation due to chronic HCV may explain some of the findings. Magnetic resonance spectroscopy and positron emission tomography scanning have demonstrated significant metabolic abnormalities in the brains of noncirrhotics with HCV, implying a low-grade inflammatory state, with the microglial cells being a focus of activation.[7, 8] In a small study, Byrnes and colleagues demonstrated that successful treatment with pegylated interferon and ribavirin led to normalisation of these central nervous system metabolic changes. Crucially, however, normalisation occurred gradually and improvement in metabolic abnormalities continued until 12 weeks post therapy, implying that the neuroinflammatory process may take time to settle after HCV therapy.[9] While the underlying mechanisms for improved quality of life are of interest, this study adds to the weight of evidence for the overall benefits of direct-acting antiviral therapies for HCV.

Editorial: direct-acting antivirals significantly improve quality of life in patients with hepatitis C virus infection—Author's reply
Z. M. Younossi

First published: 17 January 2018
DOI: 10.1111/apt.14481

Linked Content
This article is linked to Younossi et al and Sanagapalli and Danta papers. To view these articles visit https://doi.org/10.1111/apt.14423 and https://doi.org/10.1111/apt.14467.

We appreciate the Editorial comments by Drs. Sanagapalli and Danta about our recent study reporting patient-reported outcomes in patients with hepatitis C virus infection who were treated with sofosbuvir (SOF), velpatasvir (VEL) with or without voxilaprevir (VOX).[1, 2] We agree with their comments and would like to emphasise the importance of these findings in the context of the “comprehensive benefit” of HCV cure.

To fully understand the comprehensive benefit of HCV treatment, we believe it is important to assess the comprehensive impact of HCV infection including all the pertinent clinical consequences (hepatic and extrahepatic manifestations of HCV infection), the impact on patient-reported outcomes (health-related quality of life or HRQL) and the economic burden of HCV (resource utilisation and cost of illness).[3] Similarly, the benefit of anti-HCV treatment must be assessed in this comprehensive manner.[3] The most clinically relevant endpoint of HCV treatment is achieving sustained virologic response (SVR), a surrogate of improving survival by reducing the hepatic and extrahepatic complications.[3] Another important endpoint of HCV treatment should be its positive impact on patient-reported outcomes, a surrogate of HCV patients' experience.[4] Finally, we must assess the impact of anti-HCV treatment on important economic outcomes (resource utilisation, cost of illness, cost-effectiveness of treatment) must also be assessed.[5] Although the total impact of HCV infection has been well established,[3, 6] the comprehensive benefit of “HCV cure” has only recently been recognised.[1-6] In this context, our study provides additional evidence that the new regimen of SOF/VEL+/-VOX not only has superior clinical outcomes (high SVR) but also improves patient-reported outcomes during treatment and after SVR.[2]

In their Editorial, the authors have reflected about the mechanism of patient-reported outcome improvement post-SVR-12; we agree that this improvement is partly related to viral eradication. It is plausible that the additional patient-reported benefits of SVR may be related to the amelioration of the inflammatory environment of chronic hepatitis, which takes longer to resolve. This “inflammatory milieu” of HCV infection may exert its influence on the brain or the periphery of the infected patients. In fact, HCV has been associated with a number of extrahepatic manifestations such as neuropsychiatric diseases, chronic fatigue and others.[7, 8] In this context, neurocognition, fatigue and their changes after SVR may be differentially affected which in turn can influence changes in patient-reported outcome scores.[7, 8] In fact, the impact of SVR on fatigue has been recently substantiated and the data have shown that while most patients with HCV improve fatigue scores post-SVR, some do not improve.[9] Furthermore, these subjects who continue to report disabling fatigue post-SVR seem to have significant comorbidities such as depression, anxiety, type 2 diabetes.[9] Nevertheless, in the majority of HCV subjects with SVR, fatigue continues to improve and seems to maximise by post-treatment week 48.[10]

In summary, we believe that the initial patient-reported outcome improvements are due to viral eradication. The subsequent improvement may be due to a number of post-SVR changes including improvement of the inflammatory milieu and its impact of HCV on the brain and other extrahepatic targets. In contrast, patients with HCV who continue to show residual patient-reported outcome impairments post-SVR seem to have other comorbidities, which will require other treatment modalities to optimise their well-being. In this context, we believe that patient-reported outcomes must be a routine part of assessment of any chronic liver disease. These assessments will complement the clinical outcomes and provide evidence for the comprehensive impact of treatment on the patients and the society.

Wednesday, January 17, 2018

Treating Chronic Hepatitis C Infection: A Call to Action for Primary Care Providers

Experts And Viewpoints, January 2018
Treating Chronic Hepatitis C Infection in Primary Care
New treatment guidelines aim to support primary care clinicians in the treatment of hepatitis C infection. 

Treating Chronic Hepatitis C Infection: A Call to Action for Primary Care Providers

Christine A. Kerr, MD; Josh S. Aron, MD
January 17, 2018

Despite a revolutionary opportunity to end the global HCV epidemic, there clearly is a need for a concerted effort to help many more people benefit from curative therapy. It is evident that we, as healthcare providers, must step up our efforts to reach and treat patients who can benefit from DAA therapy. Only 9% of the 4 million Americans living with HCV have been successfully treated.

Thursday, January 11, 2018

The Hepatitis C Trust launches 'Eliminating Hepatitis C in Scotland' report

The Hepatitis C Trust has today launched a new report, ‘Eliminating Hepatitis C in Scotland: A Call to Action’. The report follows an inquiry conducted by The Hepatitis C Trust and the cross-party Scottish Hepatitis C Parliamentary Champions group over the course of 2017, which involved oral evidence sessions and the submission of written evidence by individuals and organisations working across the hepatitis C patient pathway.
On the basis of this evidence, The Hepatitis C Trust produced the ‘Eliminating Hepatitis C in Scotland’ report, which looks in detail at Scotland’s approach to hepatitis C, including:
  • Elimination strategy
  • Awareness
  • Prevention
  • Testing and diagnosis
  • Linkage to care
  • Access to treatment
  • Funding
The report calls on the Scottish Government to produce a hepatitis C elimination strategy, with ambitious targets to decrease national incidence, mortality and overall prevalence. Additional recommendations on awareness-raising, prevention, testing and treatment are contained in the report, and include calls for:
  • An introduction of opt-out testing for hepatitis C in substance misuse services, with commissioning contracts stipulating clear mechanisms to hold services to account for failures to meet testing targets.
  • National guidance to be issued on effective implementation of opt-out testing in prisons.
  • Treatment cost reductions to be reinvested into additional treatments or services to ensure access to treatment is available to all who need it.
  • The Scottish Government to explore alternative treatment funding models offering the opportunity to rapidly increase the number of patients receiving treatment.
Charles Gore, Chief Executive of The Hepatitis C Trust said: “Without renewed efforts to find and treat the thousands of undiagnosed patients living with hepatitis C, Scotland may no longer be considered a world leader in tackling this deadly virus.
Eliminating a public health issue that disproportionately affects some of the poorest and most marginalised groups in our society is an extraordinary and eminently achievable opportunity which should be seized with both hands.”
The full report can be accessed here

Ira M. Jacobson MD: 8-week therapy for patients with HCV infection

Clinical Care Options 
How New Data From AASLD 2017 Inform the Use of 8-Week Regimens for HCV
Ira M. Jacobson MD - 1/9/2018
Several studies presented at the 2017 AASLD meeting in Washington, DC, assessed 8-week therapy for patients with HCV infection. In this commentary, I discuss how key data from these studies may have an impact on management of patients with HCV infection.

Studies discussed:
8-Week GZR/EBR for Treatment-Naive, Noncirrhotic Patients With Genotype 1b HCV Infection
GLE/PIB for Treatment-Naive Genotype 3 HCV
8-Week LDV/SOF for Acute Genotype 1 or 4 HCV and HIV Coinfection

New At Clinical Care Options 
New Insights on NAFLD/NASH From AASLD 2017
Philip Newsome PhD, FRCPE - 1/8/2018
Here’s my take on how new data from AASLD 2017 on noninvasive imaging modalities and emerging investigational agents may affect the NAFLD/NASH patient management landscape.

How Injection Drug Use Affects HCV Treatment
Norah Terrault MD, MPH - 1/3/2018
Here’s my take on why colocalization of HCV treatment with other medical and social services may be ideal for persons who inject drugs. 

What Complications Can Arise From Percutaneous Liver Biopsy?

AGA Journals 
What Complications Can Arise From Percutaneous Liver Biopsy?
A unique complication of portal vein thrombosis after a percutaneous liver biopsy is reported in the January issue of Clinical Gastroenterology and Hepatology.

Liver biopsies are collected to aid in diagnosis of liver disease and staging of fibrosis, but complications can include pain, bleeding, puncture of another organ, and rare events such as biliary peritonitis, sepsis and shock, bilious pleural effusion, pseudoaneurysm of intercostal artery, and fragmentation of the biopsy needle.

Nicole Boschuetz et al report the case of a 64-year-old woman who had 25 days of dull constant right upper quadrant abdominal pain that began 1 day after a percutaneous liver biopsy. She had previously undergone cholecystectomy and sphincterotomy for reported sphincter of Oddi dysfunction.

Wednesday, January 10, 2018

Effect of ombitasvir/paritaprevir/ritonavir + dasabuvir regimen on health-related quality of life for patients with hepatitis C

Accepted Article

Effect of ombitasvir/paritaprevir/ritonavir + dasabuvir regimen on health-related quality of life for patients with hepatitis C
Sammy Saab, Darshan Mehta, Stacie Hudgens, Nathan Grunow, Yanjun Bao, Brett Pinsky
Accepted manuscript online: 5 January 2018
DOI: 10.1111/liv.13690

Full-text article
Downloaded & shared by @HenryEChang via Twitter.
View Article: https://jumpshare.com/v/HJEqCzaQ8N23yhY1Bwoq

Background and Aims 
This study analyzes health related quality of life (HRQoL) data from 8 randomized clinical trials using ombitasvir/paritaprevir/ritonavir and dasabuvir (3D) ± ribavirin [RBV] to investigate: [1] the impact of the treatment vs. placebo during treatment on HRQoL; [2] the sustainability of such treatment effect after 12-week treatment period; and [3] if results from [1] and [2] differ in subgenotypes 1a vs. 1b.

Six registration trials and 2 post-approval trials were pooled and analyzed using longitudinal mixed models (MM) to estimate the effect of 3D + RBV on HRQoL outcomes adjusting for baseline scores, as well as patient demographics and clinical characteristics.

Patients treated with RBV free 3D regimen reported statistically significant increase in HRQoL outcomes as compared to placebo patients. While 3D+RBV treatment saw statistically significant decline in HRQoL outcomes during treatment vs. baseline and vs. placebo, effect on HRQoL outcomes associated with RBV did not persist in the post treatment period for 3D patients followed for up to 52 weeks. The analysis also found GT1b patients reported greater improvements in HRQoL as compared to GT1a patients.

During active treatment period, small but statistically significant decrements in HRQoL outcomes were observed potentially driven by RBV, which were not sustained during the post treatment follow up period. Differences were observed by patient subgenotype, where HRQoL improvements were consistently higher for GT1b patients as compared to GT1a patients.

2018: Hepatocellular carcinoma - Updated and evidence-based review

The Lancet

Hepatocellular carcinoma 
Alejandro Forner, MD, MD Alejandro Forner
Published: 04 January 2018
DOI: http://dx.doi.org/10.1016/S0140-6736(18)30010-2

Hepatocellular carcinoma appears frequently in patients with cirrhosis. Surveillance by biannual ultrasound is recommended for such patients because it allows diagnosis at an early stage, when effective therapies are feasible. The best candidates for resection are patients with a solitary tumour and preserved liver function. Liver transplantation benefits patients who are not good candidates for surgical resection, and the best candidates are those within Milan criteria (solitary tumour ≤5 cm or up to three nodules ≤3 cm). Image-guided ablation is the most frequently used therapeutic strategy, but its efficacy is limited by the size of the tumour and its localisation. Chemoembolisation has survival benefit in asymptomatic patients with multifocal disease without vascular invasion or extrahepatic spread. Finally, sorafenib, lenvatinib, which is non-inferior to sorafenib, and regorafenib increase survival and are the standard treatments in advanced hepatocellular carcinoma. This Seminar summarises the scientific evidence that supports the current recommendations for clinical practice, and discusses the areas in which more research is needed....

Full-text article
Downloaded & shared by @HenryEChang via Twitter.
View Article: https://jumpshare.com/v/La5WS4Mn8Uwpi927nbeU

Tuesday, January 9, 2018


American Journal of Public Health Podcast
Jan 9, 2018
Hello and welcome to AJPH February 2018 podcast. This month we will be discussing the very worrisome epidemic of hepatitis C occurring in the United States. I first review with Professor Kimberly Page from the University of New Mexico how likely it is that, in a foreseeable future, the epidemic of hepatitis C could be controlled by a vaccine. Then the CDC epidemiologist Alice Asher explains why the epidemic is exacerbated by another epidemic of injection drug use, in particular of opioids, and why it is affecting young, non Hispanic white populations in the Appalachian region. And with Dr John Wong, clinical decision maker from Tufts University, we discuss how the availability of effective treatments may have transformed the prognosis of newly infected persons.

Listen Online

Healio - Herbal, dietary supplement-induced liver injury more common in young women

Herbal, dietary supplement-induced liver injury more common in young women
Medina-Cáliz I, et al. Clin Gastroenterol Hepatol. 2017;doi:10.1016/j.cgh.2017.12.051.
January 9, 2018

Analysis of the Spanish Drug-Induced Liver Injury registry showed that cases of herbal and dietary supplement-induced liver injury were more common in young women than older patients or men and correlated with hepatocellular injury and high levels of transaminases.

“Herbal and dietary supplement-induced liver injury is an increasing healthcare problem,” Inmaculada Medina-Cáliz, PhD, from the University of Málaga, Spain, and colleagues wrote. “In contrast to medicinal products including Traditional Herbal Medicinal Products which are regulated in the European Union with regard to efficacy, safety and quality standards, the lack of regulation of ‘natural’ dietary supplemental products, together with the limited awareness of physicians and consumers about possible harmful effects of these supplements, reflect the need for research and reporting in this field.”

CDC Flu Update: Influenza Activity Spikes

CDC Flu Update: Influenza Activity Spikes
Influenza activity increased sharply again in this week’s FluView report from the Centers for Disease Control and Prevention (CDC). The number of jurisdictions experiencing high activity went from 21 states to 26 states and New York City and the number of states reporting widespread activity went from 36 to 46. Influenza-like illness (ILI) went from 4.9% to 5.8%. ‎These indicators are similar to what was seen at the peak of the 2014-2015 season, which was the most severe season in recent years. Typically, severity indicators (e.g., hospitalization rates) lag behind activity indicators (ILI and geographic spread). CDC continues to recommend influenza vaccination as flu viruses are likely to continue circulating for weeks. In addition, in the context of widespread influenza activity, CDC is reminding clinicians and the public about the importance of antiviral medications for treatment of influenza in people who are severely ill and people who are at high risk of serious flu complications....
Continue to article: http://www.infectioncontroltoday.com/news/2018/01/cdc-flu-update-influenza-activity-spikes.aspx

The flu is here — and so is a new advisory from the CDC Posted
January 10, 2018
Robert H. Shmerling, MD, Faculty Editor, Harvard Health Publications
It seems like we hear the same thing every flu season — it’s going to be bad this year. In fact, different years bring different strains of flu, and the numbers of cases, complications, hospitalizations, and deaths related to the flu vary from year to year.

The CDC has just issued an advisory. Here are the highlights:
Flu season is heating up. The number of cases is rising and..

Best Practice Testing Failed to ID Hidden HCV Infections

Medscape News
Best Practice Testing Failed to ID Hidden HCV Infections
Veronica Hackethal, MD
January 08, 2018

A best practices strategy to improve detection of hepatitis B (HBV) and HCV virus infections had high uptake but failed to find undiagnosed HCV infections, a study found.

The study, published online January 8 in the Annals of Family Medicine, is the first conducted in Europe to use a strategy that combines public health and primary care in birth cohort testing of hotspots with high HCV prevalence.

"Because no active HCV infections were found in the identified hotspots, it is likely that the strategy taken would not be effective in other areas of the Netherlands and other low-prevalence countries," Jeanne Heil, MSc, from the Public Health Service, South Limburg, Heerlen, the Netherlands, and colleagues write...

Monday, January 8, 2018

Repeated influenza vaccination helps prevent severe flu in older adults

Repeated influenza vaccination helps prevent severe flu in older adults
Canadian Medical Association Journal

Repeated vaccination for influenza in older adults reduced the severity of the virus and reduced hospital admissions, found new research published in CMAJ (Canadian Medical Association Journal)

A team of Spanish researchers looked at the effect of repeated influenza vaccinations in the current and 3 previous seasons in people aged 65 years and older admitted to 20 Spanish hospitals in 2013/14 and 2014/15 to determine whether repeat vaccination reduced severe influenza.

They found repeated influenza vaccination was twice as effective in preventing severe influenza in people admitted to hospital for the virus, compared with nonsevere cases, and that this effect was consistent regardless of flu season, virus subtypes or age of patient.

"Repeated vaccination for influenza was highly effective in preventing severe and fatal infection caused by influenza in older adults," write Dr. Itziar Casado and Dr. Jesús Castilla, Instituto de Salud Pública de Navarra, Pamplona, Spain, with coauthors.

The study adds to findings from previous research that shows influenza vaccination reduces severity of the illness.

"Because severe cases of influenza may be prevented by 2 mechanisms, the effectiveness of vaccination against severe influenza may be greater than that for mild cases, and the benefit of influenza vaccination may be greater than that estimated in previous studies. The prevention of severe and fatal infection caused by influenza was observed mainly in patients who were vaccinated in both the current and previous seasons, which reinforces the recommendation of annual vaccination for influenza in older adults," the authors conclude

Epclusa - Study Backs Hepatitis C Treatment in Injection Drug Users

Study Backs Hepatitis C Treatment in Injection Drug Users
By Amy Orciari Herman
Edited by Susan Sadoughi, MD, and André Sofair, MD, MPH

Use of sofosbuvir-velpatasvir to treat hepatitis C virus (HCV) infection in injection drug users usually leads to a sustained virologic response at 12 weeks, according to an industry-supported study in the Lancet Gastroenterology & Hepatology.

Management of chronic hepatitis B before and after liver transplantation

Review Article
Management of chronic hepatitis B before and after liver transplantation
B Wang, K Agarwal, D Joshi

Chronic hepatitis B infection is a global public health problem associated with significant morbidity and mortality. Persistent infection may evolve to liver cirrhosis and hepatocellular carcinoma, and hepatitis B-related liver disease is a common indication for liver transplantation. Patients with advanced liver disease should be treated with antiviral therapy which may result in clinical improvement. The management of patients after liver transplant then focuses on preventing hepatitis B recurrence in the graft. With the introduction of prophylactic treatment, patient and graft survival has improved significantly. In this review, we will discuss the management of patients with hepatitis B-related cirrhosis, both compensated and decompensated. We also review the management of hepatitis B after liver transplantation

Full Text

Downloaded and shared by Henry E. Chang via Twitter

Sunday, January 7, 2018

Considering A Dry January? If Not - Let's Talk About Liver Disease

Considering A Dry January? If Not - Let's Talk About Liver Disease
Greetings, will you be changing any bad habits this year? If you consume too much alcohol why not take part in the "Dry January" campaign. Could one month of giving up alcohol improve your heath? Today over at NPR, Dr. Rajiv Jalan, talks about the science behind just that, listen to program, here.

The Effects Of Alcohol On The Body
The benefits of participating in a Dry January may be an effective stepping stone to giving up alcohol completely in the future. If you abuse alcohol consider this, the effect of alcohol on your body begins early on, but long-term use of alcohol can take a serious toll on your liver causing fibrosis, cirrhosis and liver cancer. Rather you drink a little or a lot, alcohol use increases your risk of developing not just liver cancer, but other cancers such as head and neck cancers, colorectal cancer, esophagus and female breast cancers. In addition, people with alcoholic liver disease and cirrhosis die more frequently from decompensation of cirrhosis than patients with cirrhosis related to chronic HCV infection or fatty liver disease, and alcohol-related liver disease has now surpassed HCV as the most common indication for liver transplant in the United States.

HCV & Alcohol 
Numerous studies have demonstrated the progression of liver disease for people with both alcohol abuse and HCV is worse when compared to people with only one disease. Those who have HCV and abuse alcohol show an increased rate of fibrosis and liver cancer, and have a higher rate of early death, compared to people with HCV who do not abuse alcohol. According to a 2016 prospective study published in the Journal of Hepatology drinking even low levels of alcohol is connected with increase risk for liver cancer in people with HCV related cirrhosis;
Whether alcohol intake increases the risk of complications in patients with HCV-related cirrhosis remains unclear. In this prospective study, light-to-moderate alcohol intake was associated with the risk of hepatocellular carcinoma in multivariate analysis. No patients who did not use alcohol and who reached viral eradication developed hepatocellular carcinoma during follow-up. The risk of hepatocellular carcinoma increased with alcohol intake or in patients without viral eradication and was highest when alcohol intake was present in the absence of viral eradication. Patients with HCV-related cirrhosis should be strongly advised against any alcohol intake. Patient care should include measures to ensure abstinence.
Read a nice summary of the article over at Healio.

In a more recent 2017 review, which explores risk of alcohol use in people with liver diseases other than alcoholic liver disease, that is people with hepatitis C, hepatitis B, fatty liver disease, and autoimmune hepatitis reported; alcohol consumption of more than 30 g per day in men and 20 g per day in women is associated with fibrosis progression, development of cirrhosis and hepatocellular carcinoma, and mortality in most liver diseases, view the article here.

How Do I Know If I Have Liver Disease Related To Alcohol?
In many cases, people who have developed liver disease associated with alcohol abuse just don't have any noticeable symptoms until their liver is badly damaged. 

What Is ALD? 
Alcohol-related liver disease or ALD, is caused by excessive consumption of alcohol overtime, the earliest stage of ALD is fatty liver disease, also called steatosis, and is the most common alcohol-related liver disorder. The next stage is alcoholic hepatitis, in which the liver cells become inflamed, finally alcoholic cirrhosis, develops when normal liver tissue is replaced by nonliving scar tissue.

Whilst many people who consume more than 60 g of alcohol a day (equivalent to half a bottle of wine or more than a litre of beer) will develop steatosis (accumulation of fat in the liver), only a minority will go on to develop the more serious condition of alcoholic liver inflammation (alcoholic hepatitis) and between 10 to 20% will develop cirrhosis (irreversible scarring of the liver). Alcohol consumption is responsible for nearly 5.9% of all deaths globally and 139 million disability-adjusted life-years lost due to premature death from alcohol.
How much Alcohol - Is Too Much?
Watch - All About Alcohol: Dr. Joe Galati
In 2017, Dr. Joe Galati discussed cutting down on alcohol and the importance of knowing the amount of alcohol in various types of alcohol and serving sizes.

The Bottom Line
Remember the best treatment for alcoholic liver disease is to not drink, hopefully your liver isn't too far damaged and can repair itself, prolonged alcohol misuse (drinking too much) over many years can reduce its ability to regenerate. As for people with HCV, not drinking is the on the list of the most important thing you can do for your liver. But you already know that.